12
Participants
Start Date
December 28, 2021
Primary Completion Date
March 1, 2024
Study Completion Date
March 1, 2024
Sevasemten
Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).
Rare Disease Research, Atlanta
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Edgewise Therapeutics, Inc.
INDUSTRY